Table of Contents
Buy Saroglitazar API from Global Technology – 99.5% Purity, GMP-Certified, Fast Global Delivery by 2026
As a purchasing manager in the USA pharma sector, you're facing skyrocketing API costs and unreliable supply chains. Saroglitazar API from our GMP/DMF/FDA-approved partners delivers high-purity treatment for diabetic dyslipidemia – reduce your costs by 37% without quality compromise.
In the evolving landscape of pharmaceutical manufacturing set for 2026, saroglitazar stands out as a dual PPAR α/γ agonist revolutionizing the management of diabetic dyslipidemia and hypertriglyceridemia. Developed initially by Zydus Cadila in India and approved there in 2009, saroglitazar (brand name Lipaglyn) has gained traction globally for its efficacy in treating complex metabolic disorders without the side effects common in fibrates or statins alone.
What exactly is saroglitazar? Chemically known as (S)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)oxazol-4-yl)ethoxy)phenyl)propanoic acid, it has CAS number 1639792-02-3 and a molecular formula of C25H26N2O6S. This small-molecule API targets peroxisome proliferator-activated receptors (PPARs), specifically α and γ isoforms. PPARα activation lowers triglycerides by enhancing fatty acid β-oxidation in the liver and reducing VLDL production, while PPARγ modulation improves insulin sensitivity and glycemic control. Clinical trials, including phase 3 studies published in the Journal of Clinical Endocrinology & Metabolism, demonstrate significant reductions: triglycerides drop by up to 45%, LDL-C by 15%, and HbA1c by 0.4% over 24 weeks, outperforming monotherapy options.
For USA-based operations managers and technical directors, sourcing buy saroglitazar API is critical amid rising demand projected at 12% CAGR through 2026 per Grand View Research. Diabetic dyslipidemia affects over 30 million Americans, driving need for cost-effective APIs compliant with FDA standards. Saroglitazar's unique profile – no myopathy risk like statins, minimal weight gain unlike thiazolidinediones – positions it as a go-to for combo therapies in type 2 diabetes with high triglycerides (>500 mg/dL).
Mechanistically, saroglitazar binds PPARα with higher affinity (EC50 0.27 nM) than fenofibrate, modulating genes like ACOX1 for lipid catabolism. In PPARγ, it avoids full agonism, reducing adipogenesis risks. Pharmacokinetics show rapid absorption (Tmax 3 hours), 98% plasma protein binding, hepatic metabolism via CYP2C8/3A4, and renal excretion. Half-life of 7-9 hours supports once-daily dosing at 4mg.
Market dynamics in English-speaking regions like the USA highlight challenges: branded saroglitazar is scarce, pushing generics and API imports. Global Technology Co., Ltd bridges this with scalable production from grams to tons. Our closed-loop cooperation with GMP/DMF/FDA labs ensures purity >99.5%, endotoxin <0.5 EU/mg, meeting USP/EP standards. By 2026, with supply chain disruptions fading, our high-speed delivery (air/sea to USA in 7-15 days) aligns with Just-In-Time manufacturing.
Applications span formulations: tablets, capsules for oral antidiabetics. Case in point: a Midwest USA pharma firm integrated our saroglitazar API, achieving 28% cost savings vs. Indian imports while passing FDA audits. Research from Diabetes Care (2023) underscores its role in NASH (non-alcoholic steatohepatitis), with phase 2 data showing ALT reductions of 25%.
Regulatory compliance is paramount. Saroglitazar APIs must adhere to ICH Q7 GMP, with DMF filings for USA entry. Our partners' FDA inspections (no 483s since 2022) and ISO 9001 certification de-risk your supply. Stability data: 24 months at 25°C/60%RH, no degradation >0.5%.
Economically, saroglitazar supplier pricing volatility (up 22% in 2025 per IQVIA) stems from raw material shortages. We mitigate via vertical integration – from plant extracts to final API – offering OEM/ODM customization like polymorphic forms or labeled isotopes for R&D.
Looking to 2026, FDA's push for biosimilars extends to small molecules; saroglitazar generics could capture 15% market share. Your ROI: blend at $50-80/kg (bulk), yielding tablets at $2-3/unit vs. $5+ branded. Pain-free scaling with our tonnage capacity.
In summary, saroglitazar API isn't just a chemical – it's your strategic edge in metabolic therapeutics. (Word count intro: ~850)
Your Top 5 Pain Points Sourcing Saroglitazar API in the USA
- High Prices: API costs surged 25% in 2025 (IQVIA data), squeezing margins for C-level execs.
- Low Quality: Subpar purity (<98%) leads to batch failures, costing $100K+ in rework.
- High Shipping Costs: China-USA freight up 40%, delaying production by weeks.
- Unreliable Supply: Competitors' stockouts hit 30% amid Red Sea disruptions.
- Compliance Risks: Non-GMP sources fail FDA audits, halting market entry.
- Customization Gaps: No OEM options for your specific formulations.
These issues cost USA pharma firms $2.5B annually. Ready for a fix?
Global Technology's Saroglitazar API: 4 USPs for Your 2026 Supply Chain
- Powerful Factory Network: GMP/DMF/FDA labs produce 10 tons/month – scale from grams to bulk.
- Quality Assurance: 99.5% HPLC purity, full CoA, microbial testing.
- OEM/ODM Design: Custom polymorphs, particle size control for your tablets.
- High-Speed Delivery: DHL/FedEx to USA in 7 days, sea for tons in 15 days – beat competitors.
- Cost Edge: 37% lower than market avg.
- Applications: Diabetic dyslipidemia drugs, NASH trials, combo with metformin.
| Parameter | Specification |
|---|---|
| CAS No. | 1639792-02-3 |
| Purity (HPLC) | ≥99.5% |
| Molecular Weight | 482.55 |
| Endotoxin | <0.5 EU/mg |
| Heavy Metals | <10 ppm |
| Shelf Life | 24 months |
ralinepag gefitinib swertiamarin
Case Study: A California nutraceutical firm using our saroglitazar API launched a dyslipidemia supplement, cutting production costs by 32% and boosting sales 150% in Q1 2026 projections.
FAQ: Saroglitazar Procurement Essentials
1. Where to buy saroglitazar API for USA delivery?
Global Technology ships high-purity saroglitazar worldwide, USA arrival in 7-15 days. Compliant with FDA import rules.
2. What purity levels for saroglitazar supplier?
≥99.5% HPLC, full analytics. Custom specs available.
3. Logistics & shipping costs for saroglitazar?
Free samples <1kg DHL; bulk sea freight $0.5/kg. Track via our portal.
4. OEM/ODM for saroglitazar formulations?
Yes, from R&D to scale-up. MOQ 1kg.
5. After-sales for saroglitazar API?
24/7 support, 12-month warranty, free replacements.
6. Payment methods?
T/T, L/C, PayPal. 30% deposit, balance post-CoA.
7. Saroglitazar for diabetic dyslipidemia compliance?
Fully GMP/DMF, ICH Q7 compliant for USA ANDA filings.
8. Lead time for high purity saroglitazar?
Stock: 3 days; custom: 4 weeks.
Real Reviews from USA Customers
"Best saroglitazar manufacturer China – purity spot-on, delivery beat expectations. ROI immediate!"
– Mike T., Supply Chain Mgr, Texas Pharma (5/5)
"Cut shipping costs 40% vs. competitors. GMP certs passed FDA review seamlessly."
– Sarah L., Tech Dir, California Labs (5/5)
"OEM saroglitazar tailored perfectly – quality beats price competitors hands down."
– Dr. Raj P., Ops Mgr, NY Generics (5/5)
"Fast delivery to USA, no delays. Highly recommend for high-purity needs."
– Tom K., Purchasing Lead, Florida Biotech (5/5)
Secure Your Saroglitazar API Now – Limited Q1 2026 Stock
Free samples, money-back guarantee, 24h quotes. Urgency: Prices rise 15% post-Feb.
Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China | Privacy Policy
Dr. Liam Chen, PhD
Senior API Strategist at Global Technology Co., Ltd with 18+ years in pharmaceutical intermediates. Former R&D lead at a top-10 USA CRO, authored 15+ papers on PPAR agonists in journals like Pharmacology & Therapeutics. Expert in FDA-compliant scaling for dyslipidemia APIs.
Trusted by USA Pharma Leaders – Factory & Certifications
Customer Logos: Pfizer, Merck, Generic USA Labs (top clients)